Medarex Announces NovImmune Filing of IND Application for Fully Human Antibody
News Jan 20, 2006
Medarex, Inc. has announced the filing of an Investigational New Drug (IND) application in the Netherlands by its licensing partner, NovImmune SA, for NI- 0401, a fully human antibody that targets the CD3 antigen, for the treatment of autoimmune disease.
The antibody product was developed using Medarex's UltiMAb® technology.
Medarex expects to receive an undisclosed milestone payment and may receive future milestone payments and royalties should this product candidate progress through clinical development.
"We are pleased with the progress that our partner, NovImmune, has achieved in filing an IND," said Donald L. Drakeman, President and CEO of Medarex, Inc.
"With the advancement of the NovImmune antibody into clinical trials, there are now twenty-nine fully human antibodies generated from Medarex's technology that are in clinical development by Medarex and its partners."
Avacta Group plc announces successful outcome of “Gene Delivery” collaboration with FIT BiotechNews
Sustained production of Affimer drugs by muscle tissue in vivo could lead to major patient and commercial benefits.READ MORE
SCRaMbLE Speeds Up Yeast EvolutionNews
Scientists have created a new way of speeding up the genome evolution of baker’s yeast Saccharomyces cerevisiae. This is to develop a synthetic yeast strain that can be transformed on demand, making it industrial applications such as the mass production of advanced medicines to treat illnesses such as malaria and tuberculosis (TB).READ MORE
Artificial Cellular Compartments BuiltNews
How to install new capabilities in cells without interfering with their metabolic processes? A team from the Technical University of Munich (TUM) and the Helmholtz Zentrum München have altered mammalian cells in such a way that they formed artificial compartments in which sequestered reactions could take place, allowing the detection of cells deep in the tissue and also their manipulation with magnetic fields.READ MORE